The field of wood claus
4D molecular therapy (Nasdak:FDMT) announced a significant decrease in the labor force by approximately 25% of current and planned positions for directing work.
The company also speeds up its 4D -50 450 4FRONT Stage 3 program aimed at treating macular degeneration associated with damp age.
Source link
